Vanguard Investments Australia
NVCR icon

Vanguard Investments Australia’s NovoCure NVCR Stock Holding History

Vanguard Investments Australia’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$438K Hold
28,900
– – ﹤0.01% 1711
2026
Q1 		$315K Buy
+28,900
New +$361K ﹤0.01% 1817

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Investments Australia's NVCR Position: Q2 2026 in Review

Vanguard Investments Australia held its NovoCure (NVCR) position steady in Q2 2026 at 28,900 shares worth $438K. The position accounts for ﹤0.01% of the portfolio, ranked #1711.

Vanguard Investments Australia first reported a position in NVCR in Q1 2026 and has held it in 2 quarters since. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Vanguard Investments Australia held 28,900 shares of NovoCure worth $438K as of Q2 2026.
  • Vanguard Investments Australia left its NovoCure share count unchanged in Q2 2026.
  • NovoCure made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1711 holding.
  • Vanguard Investments Australia first reported a position in NovoCure in Q1 2026 and has held it in 2 quarters since.
  • 216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.